Physician profile
Menthola Smith
NPI 1558987990
$3,735.50
in general payments reported to CMS, 2019-2025
20 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $319 · 2023: $892 · 2024: $1,202 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,410 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,410.24 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $773.68 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $738.35 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $646.55 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $403.70 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $360.78 | 2022-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $293.29 | 2024-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $82.10 | 2023-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.51 | 2022-2023 | Jardiance, Synjardy |
| Amgen INC. | $62.44 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.13 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $51.39 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $38.27 | 2024 | Veozah |
| Shield Therapeutics INC | $38.17 | 2023-2024 | Accrufer |
| Corcept Therapeutics | $21.92 | 2024 | Korlym |
| Ironwood Pharmaceuticals, INC | $21.34 | 2023 | Linzess |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $20.81 | 2025 | Xyosted |
| Abbvie INC. | $20.52 | 2024 | |
| Sumitomo Pharma America, INC. | $16.06 | 2025 | Gemtesa |
| Atland Pharmaceuticals, LLC | $15.67 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Alnylam Pharmaceuticals INC. | $13.82 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Menthola Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.